RESEARCH QUESTION 1:
Changes in Mental Health Symptoms
Eligible studies must report changes in symptom levels, the proportion of participants above a cutoff threshold, or the proportion of participants who change by a pre-defined magnitude (e.g., minimal clinically important difference) across a delineated COVID-19 related event. This could include comparisons of pre-COVID-19 and COVID-19 symptoms, symptoms at the initiation of the outbreak to the peak, or symptoms during highly restrictive isolation periods to subsequent periods, for instance. Studies with < 100 participants are excluded.
We are not including cross-sectional studies that report percentages of participants with scores above cutoff thresholds on commonly used symptom questionnaires. Conclusions that can be drawn from that type of data about mental health effects from COVID-19 and clinical implications, however, are limited, and, per our protocol, we have not included those studies. This is because percentages of people who score above a threshold on standardized questionnaires vary, sometimes dramatically, between populations, even in normal times. For example, the percentage of participants with scores of at least 10 on the Patient-Health Questionnaire-9, a commonly used measure of depressive symptoms, in large, randomly selected, regional or national general population samples, has been reported as 4% in Hong Kong (N = 6,028); 6% in Germany (N = 5,018); 7% in Shanghai, China (N = 1,045); 8% in the United States (N = 10,257); 8% in the province of Alberta, Canada (N = 3,304); 11% in Sweden (N = 3,001); and 22% in Jiangsu Province, China (N = 8,400). Even within populations from the same region, the percentage can vary dramatically depending on sample characteristics. In Jiangsu Province, for example, the percentage among rural residents (32%) is twice that of urban residents (16%); it is also several times higher for older adults (25% for 55-64 years; 87% for ≥ 65 years) than for young adults (8% for 18-34 years). Further complicating interpretation when there is not a time-based or other relevant comparator, percentages from symptom measures such as the PHQ-9 tend to dramatically overestimate prevalence that would be obtained from validated methods for ascertaining prevalence of mental health disorders, and there is too much heterogeneity between samples in the difference to correct for this statistically.
Preprint compared mental health symptoms prior to and during COVID-19 in the general population and other population groups has posted on medRxiv. Click HERE to check the results.
1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613.
2. Yu X, Tam WWS, Wong PTK, Lam TH, Stewart SM. The Patient Health Questionnaire-9 for measuring depressive symptoms among the general population in Hong Kong. Compr Psychiatry. 2012;53:95-102.
3. Kocalevent RD, Hinz A, Brähler E. Standardization of the depression screener Patient Health Questionnaire (PHQ-9) in the general population. Gen Hosp Psychiatry. 2013;35:551-555.
4. Wang W, Bian Q, Zhao Y, et al. Reliability and validity of the Chinese version of the Patient Health Questionnaire (PHQ-9) in the general population. Gen Hosp Psychiatry. 2014;36:539-544.
5. Cao C, Hu L, Xu T, et al. Prevalence, correlates, and misperception of depression symptoms in the United States, NHANES 2015-2018. J Affect Disord. 2020;269:51-57.
6. Patten SB, Schopflocher D. Longitudinal epidemiology of major depression as assessed by the Brief Patient Health Questionnaire (PHQ-9). Compr Psychiatry. 2009;50:26-33.
7. Johansson R, Carlbring P, Heedman A, Paxling B, Andersson G. Depression, anxiety and their comorbidity in the Swedish general population: point prevalence and the effect on health-related quality of life. PeerJ. 2013;1:e98.
8. Lu S, Reavley N, Zhou J, et al. Depression among the general adult population in Jiangsu Province of China: prevalence, associated factors and impacts. Soc Psychiatry Psychiatr Epidemiol. 2018;53:1051-1061.
9. Levis B, Benedetti A, Ioannidis JPA, et al. Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: an individual participant data meta-analysis. J Clin Epidemiol. 2020;122:115-128.
Country of participants: Among 79 eligible studies, Argentina (N=2), Australia (N=3), Brazil (N=1), Canada (N=3), Croatia (N=1), Cyprus (N=1), China (N=23), Czech Republic (N=1), Denmark (N=2), France (N=1), Germany (N=1), India (N=2), Ireland (N=1), Italy (N=4), Israel (N=2), Japan (N=4), New Zealand (N=1), Spain (N=4), Switzerland (N=2), Sweden (N=1), The Netherlands (N=4), UK (N=21), USA (N=19)
*Abbreviations: BDI= Beck’s Depression Inventory; BJSQ= Brief Job Stress Questionnaire; BRUMS= Brunel Mood Scale; BSI-18= Brief Symptom Inventory; CDI= Children’s Depression Inventory; CES-D= Center for Epidemiologic Studies Depression Scale; DASS-21= Depression, Anxiety, and Stress Scale; DJGLS-emotional loneliness= De Jong Gierveld Loneliness Scale-emotional loneliness; DJGLS-social loneliness= De Jong Gierveld Loneliness Scale-social loneliness; DToS= Distress Tolerance Scale; FDI= Filgueiras Depression Inventory; GAD-2= Generalized Anxiety Disorder 2-item GAD-7= Generalized Anxiety Disorder 7-item; GHQ 12= General Health Questionnaire; HADS-A= Hospital Anxiety and Depression Scale- Anxiety; HADS-D= Hospital Anxiety and Depression Scale- Depression; HAM-A= Hamilton Anxiety Rating Scale; HAM-D= Hamilton Rating Scale for Depression; HBQ= MacArthur Health and Behavior Questionnaire; K10=.Kessler Psychological Distress Scale; K6= Kessler Psychological Distress Scale Short Version; MBI= Maslach Burnout Inventory; MDI= Major Depression Inventory; MFQ= Mood and Feelings Questionnaire; MHI-5= The five-question Mental Health Inventory; PANAS= Positive and Negative Affect Schedule; PCL-C= PTSD Checklist-Cuvukuab Version; PHQ 2= Patient Health Questionnaire 2; PHQ 4= Patient Health Questionnaire 4; PHQ 8= Patient Health Questionnaire 8; PHQ 9= Patient Health Questionnaire 9; PGC= Philadelphia Geriatric Center Positive and Negative Afect Scales; PQEEPH= Psychological Questionnaires for Emergent Events of Public Health; PROMIS= Patient Reported Outcomes Measurement Information System; PSS= Perceived Stress Scale; RRQ= Reflection and Rumination Scale; SCAS= Spence Children's Anxiety Scale; SCL-90= Symptom Check List-90; SDQ= The Strengths and Difficulties Questionnaire; SF 12=12-Item Short Form Survey; SMFQ= Short Mood and Feelings Questionnaire; STAI= State Trait Anxiety Inventory; TLS= Three-Item Loneliness Scale; WEMWBS= Warwick Edinburgh Mental Wellbeing Scale; ULS-3= University of California, Los Angeles (UCLA) Loneliness Scale 3; ULS-9= University of California, Los Angeles (UCLA) Loneliness Scale 9; ULS-11= University of California, Los Angeles (UCLA) Loneliness Scale 11; WHO-5= WHO (Five) Wellbeing Index; YUSS= Yang Uncertainty Stress Scale; ZSAS= Zung Self-rating Anxiety Scale; ZSAS= Zung Self-rating Depression Scale
*A positive effect size indicates an increase in the construct assessed